Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Total Debt (2016 - 2025)

Haemonetics has reported Total Debt over the past 16 years, most recently at $1.2 billion for Q4 2025.

  • For Q4 2025, Total Debt changed 0.01% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, changed 0.01%, while the annual FY2025 figure was $1.2 billion, 51.62% up from the prior year.
  • Total Debt for Q4 2025 was $1.2 billion at Haemonetics, roughly flat from $1.2 billion in the prior quarter.
  • Over five years, Total Debt peaked at $1.2 billion in Q3 2024 and troughed at $707.6 million in Q2 2021.
  • A 5-year average of $936.1 million and a median of $796.1 million in 2021 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: skyrocketed 150.89% in 2022 and later decreased 6.79% in 2023.
  • Year by year, Total Debt stood at $780.8 million in 2021, then dropped by 1.79% to $766.8 million in 2022, then grew by 13.54% to $870.6 million in 2023, then soared by 40.69% to $1.2 billion in 2024, then decreased by 0.01% to $1.2 billion in 2025.
  • Business Quant data shows Total Debt for HAE at $1.2 billion in Q4 2025, $1.2 billion in Q3 2025, and $1.2 billion in Q2 2025.